Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-005038
Filing Date
2019-05-15
Accepted
2019-05-15 07:23:37
Documents
48
Period of Report
2019-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mlnd-20190331x10q.htm 10-Q 1658776
2 EX-3.1 mlnd-20190331ex31b53fa83.htm EX-3.1 95790
3 EX-31.1 mlnd-20190331ex311206b62.htm EX-31.1 11503
4 EX-31.2 mlnd-20190331ex31212cad4.htm EX-31.2 11466
5 EX-32.1 mlnd-20190331ex3218459f4.htm EX-32.1 10414
  Complete submission text file 0001558370-19-005038.txt   4285875

Data Files

Seq Description Document Type Size
6 EX-101.INS mlnd-20190331.xml EX-101.INS 570488
7 EX-101.SCH mlnd-20190331.xsd EX-101.SCH 26192
8 EX-101.CAL mlnd-20190331_cal.xml EX-101.CAL 45619
9 EX-101.DEF mlnd-20190331_def.xml EX-101.DEF 79074
10 EX-101.LAB mlnd-20190331_lab.xml EX-101.LAB 326606
11 EX-101.PRE mlnd-20190331_pre.xml EX-101.PRE 217830
Mailing Address 301 NORTH MAIN STREET, SUITE 100 ANN ARBOR MI 48104
Business Address 301 NORTH MAIN STREET, SUITE 100 ANN ARBOR MI 48104 734-845-9000
Millendo Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

EIN.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35890 | Film No.: 19825069
SIC: 2834 Pharmaceutical Preparations